IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Mareke Hartig, et al.) Art Unit: 1615

U.S. Appln. No. : 10/718,404) Examiner: Carlos A. Azpuru

Confirmation No.: 9739 U.S. Filing Date: 11/20/2003

Title of Invention: Tiotropium Containing Powder Formulation For Inhalation

Attny, Docket No.: 1/1425

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

REPLY TO OFFICE ACTION UNDER 37 C.F.R. § 1.111

Sir:

This Reply is being filed in response to the December 12, 2007 Office Action issued in the above-identified application. In that Office Action, a three-month shortened statutory period was set for response. Applicants hereby petition for a three-month extension of time under 37 C.F.R. § 1.136 to respond to that action and note that the fee required under 37 C.F.R. § 1.17(a) in connection with this extension of time will be paid during electronic filing via the Revenue Accounting and Management System.

Furthermore, if it is determined that any additional fees under 37 C.F.R. §§ 1.16 or 1.17 are due in connection with this Reply, authorization to charge such fees to Deposit Account No. 02-2955 will be provided during electronic filing.

A Listing of Claims begins on page 2 of this paper.

Remarks begin on page 3 of this paper.